Darier Disease with Generalized Skin Lesions When Supportive Care Has Not Controlled Pruritus

This protocol covers disseminated (non-localized) Darier disease in patients whose pruritus and skin irritation have not improved adequately with supportive and symptomatic management. When first-line measures are insufficient, escalation to systemic therapy is the structured next step.

Prior Treatment — Target Not Reached

Supportive/symptomatic care — comprising emollients, soap substitutes, cotton clothing, sun protection in photoaggravated cases, and strict avoidance of known exacerbating factors — did not achieve the target goal of improvement in pruritus and skin irritation. Failure to reach this target defines the indication for escalation to the next line.

Clinical Scenario

The patient presents with disseminated or generalized Darier disease: skin lesions are widespread rather than confined to a limited area. This extent of involvement places the case beyond the scope of supportive measures alone and supports the use of systemic oral therapy.

Next-Line Treatment Approach

Oral retinoid therapy is the established systemic class for generalized Darier disease at this stage. Several agents within this class carry documented evidence of benefit. The specific choice of agent and the individualized dosing and adjustment strategy are set out in the full structured protocol.

Treatment Goal

Clinical improvement of the skin lesions, expected within 1 to 4 weeks of initiating treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.25259/IJDVL_963_19

Oral retinoids were the most effective oral therapy and were prescribed in the cases of generalized Darier disease.
Burge et al. were the first to use oral etretinate in 1981, at a dose of 0.5–1.0 mg/kg in 18 patients with Darier disease, 17 of which improved.
Efficacy of acitretin in Darier disease was assessed in 1 case series where 4 out of the 5 patients improved, using starting doses of 35 mg daily for the first 3 months then adjusting the dose according to the response.
In another article, acitretin was used to treat 13 patients with a dose starting at 30 mg per day for 16 weeks.
The starting dose that was used was 0.5 mg/kg and the maintenance dose was adjusted according to symptoms.
It was found to be very effective with 73 (70%) patients showing clinical improvement after 1 to 4 weeks according to both patients and the physicians.

View source ↗